Growth hormone deficiency in childhood acute lymphoblastic leukemia survivors – should systematic stimulation test be performed in all irradiated children?

Damasio, Ines; Cavaco, Daniela; Maciel, Joana; Dias, Daniela; Donato, Sara; Pinheiro, Sara; Figueiredo, Ana; Simões‐Pereira, Joana; Pereira, C.

doi:10.1530/endoabs.70.aep620

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28) Another study reported 120 cases of GHD among 324 ALL patients (37%) diagnosed over 40 years. 29) In our study, the prevalence of GHD in leukemia patients was approximately 1:60, much higher than in the general population. The higher prevalence in this study is thought to be related to leukemia treatments, such as chemotherapy and radiation treatment.…”

Section: A C C E P T E D a R T I C L Econtrasting

confidence: 41%

Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency

Shin¹,

Jang²,

Kim³

et al. 2023

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Purpose: Survivors of childhood leukemia are at risk of growth impairment due to intensive chemotherapy and radiation treatment. This study investigated the auxological and biochemical characteristics of childhood leukemia survivors diagnosed with growth hormone deficiency (GHD) and the changes in these parameters after 1 year of growth hormone (GH) treatment.Methods: A total of 24 children diagnose with GHD after leukemia treatment were analyzed. Clinical and biochemical data were collected retrospectively at leukemia diagnosis, GHD diagnosis, and 1 year after GH treatment. Standard deviation score (SDS) was calculated based on the age-and genderadjusted population.Results: Of the 24 children included in this study, 19 received GH treatment. The median age at GHD diagnosis was 12.3 years, and the median delay in bone age was 1.46 years. Height SDS decreased from -0.69 at leukemia diagnosis to -2.58 at GHD diagnosis (p < 0.001). Change in height SDS with and without GH for 1 year was 0.35 and -0.21, respectively (p = 0.044). In regression analyses, higher height SDS at GHD diagnosis and less decrement of the height SDS between leukemia and GHD diagnoses were positively correlated with height SDS after GH treatment. Conclusion:GH treatment could be beneficial and safe for improving height in childhood leukemia survivors with GHD. Height SDS at GHD diagnosis and decrement of height SDS between leukemia and GHD diagnosis could be a potential factor in predicting the therapeutic effect. Close auxological monitoring is recommended for any childhood leukemia survivors who experience post-treatment height decline.

show abstract

Section: A C C E P T E D a R T I C L Econtrasting

confidence: 41%